{"id":"saquinavir-invirase","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Gastrointestinal disturbances (diarrhea, nausea)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Elevated liver enzymes"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL4575419","moleculeType":"Unknown","molecularWeight":"670.86"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Saquinavir is a protease inhibitor that binds to the active site of HIV protease, a viral enzyme essential for processing precursor proteins into functional viral components. By blocking this enzymatic activity, the drug prevents the formation of mature, infectious viral particles, thereby reducing viral replication and slowing disease progression in HIV-infected patients.","oneSentence":"Saquinavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:54.397Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (in combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00445146","phase":"PHASE2","title":"Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2007-02","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT00623597","phase":"PHASE2","title":"A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-06","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT00622141","phase":"PHASE1, PHASE2","title":"Bioequivalence Study of Generic GPO Saquinavir and Norvir® Versus Invirase® and Norvir®","status":"WITHDRAWN","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT02184286","phase":"PHASE1","title":"Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"1999-05","conditions":"HIV Infections","enrollment":5},{"nctId":"NCT00400738","phase":"PHASE2","title":"The Pharmacokinetics of Double Boosted Protease Inhibitors in Antiretroviral-naive HIV-1 Infected Patients","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2004-03","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT00438152","phase":"PHASE4","title":"Lopinavir Capsules to Kaletra or Invirase Tablets","status":"COMPLETED","sponsor":"Royal Free Hampstead NHS Trust","startDate":"2006-09","conditions":"HIV Infections","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Invirase®"],"phase":"marketed","status":"active","brandName":"Saquinavir (Invirase®)","genericName":"Saquinavir (Invirase®)","companyName":"Royal Free Hampstead NHS Trust","companyId":"royal-free-hampstead-nhs-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Saquinavir inhibits HIV protease, preventing the cleavage of viral polyproteins and blocking the maturation of infectious HIV particles. Used for HIV-1 infection (in combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}